The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4 + T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway

摘要: Vaccination remains the most cost-effective biomedical approach for controlling influenza disease. In times of pandemics, however, these vaccines cannot be produced in sufficient quantities worldwide use by current manufacturing capacities and practices. What is needed development adjuvanted capable inducing an adequate or better immune response at a decreased antigen dose. Previously we showed that protein adjuvant rOv-ASP-1 augments influenza-specific antibody titers survival after virus challenge both young adult old-age mice when administered with trivalent inactivated vaccine (IIV3). this study show reduced amount rOv-ASP-1, 40-times less IIV3 can also induce protection. Apparently potency independent IIV3-specific Th1/Th2 associated responses, presence HAI antibodies. However, CD4+ T helper cells were indispensable Further, without elicited increased level various chemokines, which are known chemoattractant cells, into muscle 4 h immunization, significantly induced recruitment monocytes, macrophages neutrophils muscles. The recruited monocytes had higher expression activation marker MHCII on their surface as well CXCR3 CCR2; receptors IP-10 MCP-1, respectively. These results allows substantial sparing stimulating site injection accumulation chemokines augment cell essential production responses. Protection appears to function absence MyD88-signaling. Future studies will attempt delineate precise mechanisms works.